MULTIVIR
MultiVir, Inc., a clinical-stage gene therapy company, engages in developing a pipeline of product candidates for the treatment of various oncological indications. The company’s lead product candidates that has completed Phase 1 clinical trials include Ad-p53, a genetically modified adenovirus designed to deliver the normal p53 tumor suppressor gene, which targets fundamental molecular defects present in various types of cancers; and Ad-IL24, a genetically engineered adenovirus modified to deliver the tumor suppressor gene interleukin-24 that has tumor suppressor activities similar to p53 and certain immunostimulatory properties.
MULTIVIR
Industry:
Biotechnology Genetics
Founded:
2009-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.multivir.com
Total Employee:
1+
Status:
Closed
Contact:
(832) 431-3555
Technology used in webpage:
SPF Mobile Non Scaleable Content PHP GoDaddy DNS GoDaddy GoDaddy Email
Current Employees Featured
Founder
Official Site Inspections
http://www.multivir.com Semrush global rank: 4.47 M Semrush visits lastest month: 935
- Host name: 113.174.62.50.host.secureserver.net
- IP address: 50.62.174.113
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "MultiVir"
Home - MultiVir
Learn more about the science supporting MultiVir’s tumor suppressor immune gene therapies and therapeutic vaccines. Contact Us Contact information for MultiVir clinical trials and …See details»
MultiVir - Crunchbase Company Profile & Funding
View contacts for MultiVir to access new leads and connect with decision-makers. MultiVir, Inc., a clinical-stage gene therapy company, engages in developing a pipeline of product candidates for the treatment of various oncological …See details»
MultiVir Inc - VentureRadar
MultiVir is a clinical stage immune oncology company pioneering new fields of cancer therapeutics termed Tumor Suppressor Immune Gene Therapy and Immune Surgery. We are advancing …See details»
Leadership Team - MultiVir
Mr. Wells has served as Chairman since December 2014 and has been a member of our board of directors since inception. Since 2000, Mr. Wells has served as President of Pope Asset …See details»
MultiVir Clinical Trials - MultiVir
MultiVir’s Ad-p53 product candidates deliver normal p53 genes into tumors to restore their tumor suppressor functions which include inhibition of tumor growth and the activation of anti-tumor …See details»
Multivir Inc - Company Profile and News - Bloomberg Markets
Multivir, Inc. provides gene therapies for cancer treatments. The Company specializes in the discovery of novel tumor suppressor and immune gene therapies based upon multiple viral …See details»
Multivir Inc. Company Profile | Houston, TX - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Multivir Inc. of Houston, TX. Get the latest business insights from Dun & Bradstreet.See details»
MultiVir - Company Profile - Tracxn
1 day ago · Developer of gene therapies to treat cancer. The company’s lead drug candidate is Ad-p53, a genetically modified adenovirus designed to deliver the normal p53 tumor …See details»
MultiVir - Overview, News & Similar companies | ZoomInfo.com
Jan 24, 2018 · MultiVir is a clinical stage immune oncology company pioneering a new field of cancer therapeutics termed tumor suppressor immune gene therapy employing multiple viral …See details»
MultiVir Company Profile - Office Locations, Competitors ... - Craft
MultiVir is an immune-oncology company developing cancer treatments based on multiple gene therapy technologies. It offers treatments that include tumor suppressor immune gene therapy …See details»
Robert E. Sobol - CEO & Founder @ MultiVir - Crunchbase
Robert E. Sobol is the CEO and Founder of MultiVir. Co-Founder of IDEC Pharmaceuticals. Robert E. Sobol, M.D. has over 25 years of entrepreneur and management experience in the …See details»
Medical Professionals - MultiVir
Our clinical trials are evaluating the safety and efficacy of MultiVir’s investigational cancer treatments called “Tumor Suppressor Immune Gene Therapy” and “Dendritic Cell Therapeutic …See details»
Developer of viral vectors for anticancer gene therapy files for …
Mar 31, 2015 · MultiVir, a developer of viral vectors to deliver anticancer gene therapy, just filed for a $70 million IPO with the Securities and Exchange Commission as it seeks funding for …See details»
MultiVir - Crunchbase
Companies like MultiVir include Context Therapeutics, Vittoria Biotherapeutics, and Scout Bio.See details»
MultiVir Reports Gene Therapy Enhancement of Cancer …
May 18, 2017 · MultiVir is conducting a clinical trial of its Ad-p53 tumor suppressor therapy in combination with another immune modulatory agent termed low dose, continuous capecitabine …See details»
MultiVir Reports Reversal of Immunotherapy Resistance by Tumor ...
Jan 25, 2018 · MultiVir is a clinical stage immune oncology company pioneering a new field of cancer therapeutics termed tumor suppressor immune gene therapy employing multiple viral …See details»
Our Clinical Trials - MultiVir
MultiVir is developing novel tumor suppressor immune gene therapy product candidates that employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to …See details»
MultiVir - Contacts, Employees, Board Members, Advisors & Alumni
MultiVir has 1 current employee profile, CEO & Founder Robert E. Sobol. Contacts. Edit Contacts Section. We're working on getting contact data for MultiVir . Find more contact data in Search! …See details»
p53 gene therapy - MultiVir - AdisInsight - Springer
Jun 28, 2021 · Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. MultiVir (formerly known as p53) is developing Ad p53, an …See details»
BIAT - Multivir
Bienvenue sur Multivir. Veuillez entrer votre nom d'utilisateur et votre mot de passe :See details»